Dermatitis Eczema Articles & Analysis
11 news found
Indications DUPIXENT is a prescription medicine used: to treat adults and children 6 years of age and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. ...
Dupixent is also approved in Europe, Japan and other countries around the world for use in specific patients with moderate-to-severe atopic dermatitis and certain patients with asthma or CRSwNP in different age populations. ...
AOBiome Therapeutics, a clinical stage biotechnology company focused on transforming human health by developing topical biologic therapies for systemic inflammatory conditions, announced positive pivotal Phase 2b results from its trial evaluating B244 in both pruritus (itch) and appearance of atopic dermatitis (eczema). The trial enrolled 547 patients with ...
AOBiome Therapeutics), a leading clinical-stage biotechnology company focusing on inflammation, announced completion of enrollment in its Phase 2b clinical trial in pruritus (itch) associated with atopic dermatitis. This trial is based on previous positive clinical trial results related to the investigation of its lead product candidate, B244, a live topical biotherapeutic, in ...
("AOBiome"), a leading clinical-stage microbiome company focusing on inflammation, announced initiation of a Phase 2b clinical trial in pruritus (itch) associated with atopic dermatitis based on positive clinical trial results related to the investigation of its lead product candidate, B244, in patients with atopic dermatitis (eczema) in a Phase ...
("AOBiome"), a leading clinical-stage microbiome company focusing on inflammation, announced initiation of a Phase 2b clinical trial in pruritus (itch) associated with atopic dermatitis based on positive clinical trial results related to the investigation of its lead product candidate, B244, in patients with atopic dermatitis (eczema) in a Phase ...
(“AOBiome”), a leading clinical-stage microbiome company focusing on the research and development of therapeutics for dermatological conditions, migraine, hypertension and other systemic diseases, today announced the administering of its lead product candidate, B244, to the first patient in the Company’s Phase 1b clinical trial to treat pediatric patients with atopic ...
AOBiome is currently conducting a Phase 2 clinical trial investigating AOB for the treatment of eczema with expected readout in 2019. In addition to its eczema trial, AOBiome is pursuing four additional indications in Phase 2, including acne where a Phase 2 study has recently concluded and the Phase 3 studies are planned to begin within the first half of 2019. ...
The company's portfolio includes six clinical-stage programs in the following indications; acne vulgaris, hypertension, eczema (atopic dermatitis), migraine, rosacea, and allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory ...
Long-term exposure causes chronically impaired lung function, skin hardening, swelling and flaking, dermatitis, allergic eczema, and cancer. PPM Technology has significant experience in the design and development of instruments for accurate detection and measurement of Formaldehyde. ...
Long-term exposure causes chronically impaired lung function, skin hardening, swelling and flaking, dermatitis, allergic eczema, and cancer. Safety and detection In order to ensure employees are not exposed to dangerous concentrations of Formaldehyde in the air, it is advised to detect and monitor levels with a suitable detection instrument. ...